Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT

Leukemia and Lymphoma

Volumn 54, Issue 1, 2013, Pages 186-188

  Khoo, Teh Liane ^a   Catalano, Alberto ^a   Supple, Shane ^a   Chong, Li ^a   Yeoh, Sue Ching ^a   Yeung, Stephen ^b   Iland, Harry ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; STEM CELL FACTOR RECEPTOR;

ADULT; ANKLE EDEMA; BLISTER; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CONJUNCTIVAL HEMORRHAGE; CYTOGENETICS; FEMALE; GENETIC VARIABILITY; HARD PALATE; HUMAN; HYPERPIGMENTATION; KARYOTYPE 46,XX; LACRIMAL GLAND DISEASE; LETTER; LEUKAPHERESIS; LEUKOCYTOSIS; PALATE DISEASE; PERIORBITAL EDEMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BENZAMIDES; FEMALE; GENETIC VARIATION; HETEROZYGOTE; HUMANS; HYPERPIGMENTATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; MUTATION; PALATE, HARD; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES;

EID: 84870862813     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.702904     Document Type: Letter

References (15)

1. O'Brien SG, Guilhot F, et al. International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009 ; 114(Suppl. 1): Abstract 1126.
2. T sao A, K antarjian H, C ortes J, et al. I matinib mesylate causes hypopigmentation in the skin. Cancer 2003; 98: 2483- 2487. (Pubitemid 37466664)
3. S ingh N, B akhshi S. I matinib-induced dental hyperpigmentation in childhood chronic myeloid leukemia. J Pediatr Hematol Oncol 2007 ; 29: 208-209. (Pubitemid 46673415)
4. Mattsson U, Halbritter S, M o rner Serikoff E, et al. Oral pigmentation in the hard palate associated with imatinib mesylate therapy: A report of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol 2011 ; 111: E12Ye16.
5. G richnik JM, B urch JA, B urchette J, et al. The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis. J Invest Dermatol 1998; 111: 233- 238. (Pubitemid 28354709)
6. Gagari E, Rand MK, Tayari L, et al. Expression of stem cell factor and its receptor, c-kit, in human oral mesenchymal cells. Eur J Oral Sci 2006 ; 114: 409-415. (Pubitemid 44526679)
7. Hemesath T, Price E, Takemoto C, et al. MAP kinase links the transcription factor Microphthalmia to c-Kit signaling in melanocytes. Nature 1998 ; 391: 298-301. (Pubitemid 28099019)
8. E tienne G, C ony-Makhoul P, M ahon F. I matinib mesylate and gray hair. N Engl J Med 2002; 347: 446.
9. A lexandrescu D, D asanu C, F arzanmehr H, et al. P ersistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST. Dermatol Online J 2008; 14(7): 7.
10. McPherson T, Sherman V, Turner R. Imatinib-associated hyperpigmentation, a side Effect that should be recognized. J Eur Acad Dermatol Venereol 2009 ; 23: 82-83.
11. Inokuchi K, Yamaguchi H, Tarusawa M, et al. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia - potential clinical significance. Leukemia 2002 ; 16: 170-177. (Pubitemid 34145133)
12. K ru g er S, E mig M, L ohse P, et al. The c-kit (CD117) sequence variation M541L, but not N564K, is frequent in the general population, and is not associated with CML in Caucasians. Leukemia 2005 ; 20: 354-355. (Pubitemid 43148677)
13. Foster R, Byrnes E, Meldrum C, et al. Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT. Br J Dermatol 2008 ; 159: 1160-1169.
14. Goncalves A, Monges G, Yang Y, et al. Response of a KIT-positive extra-abdominal fi bromatosis to imatinib mesylate and KIT genetic analysis. J Natl Cancer Inst 2006 ; 98: 562-563. (Pubitemid 43898822)
15. Murakami T, Fukai K, Oiso N, et al. New KIT mutations in patients with piebaldism. J Dermatol Sci 2004; 35: 29- 33. (Pubitemid 38759738)